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Background
Corticosteroids are drugs that can reduce the inflamma-
tion caused by infection, used as an adjunct to antimicro-
bial drugs to improve the outcome in various infectious
diseases, but their role is controversial. Research on the
use of corticosteroids in addition to antimicrobials has had
conflicting results. Corticosteroids are also known to have
certain adverse effects.
Methods and results
We have studied the Cochrane systematic reviews
addressing the systemic use of corticosteroids in:
• acute bacterial meningitis (to examine the effect ver-
sus placebo on mortality, hearing loss and neurological
sequelae in participants of all ages); 24 randomized con-
trolled trials (RCTs) enrolling 4041 patients;
• tuberculous meningitis (to examine the effect on
death or disabling residual neurological deficit); 7 RCTs
involving 1140 people;
• infectious mononucleosis (to assess efficacy and
safety of steroids for symptom control); 4 trials that
compared the effectiveness of a steroid for short-term
symptom control to a placebo and 3 other trials that
used a combination of steroid and an antiviral drug,
involving 362 participants;
• acute sinusitis (to assess the effectiveness of systemic
corticosteroids in relieving symptoms); 4 RCTs with a
total of 1008 adult participants;
• acute pharyngitis (to assess the clinical benefit and
safety of corticosteroids for symptoms of sore throat in
adults and children) 8 trials involving 743 participants
(369 children and 374 adults);
• acute pneumonia (to assess efficacy and safety of
corticosteroids), 6 studies including 437 participants;
• croup in children (to determine the effect of gluco-
corticoids), 38 studies were included, enrolling 4299
patients;
• acute viral bronchiolitis in children (to evaluate the
efficacy and safety of systemic and inhaled glucocorti-
coids), 17 trials with 2596 participants;
• severe sepsis and septic shock (to examine the effects
of corticosteroids on death at one month in sepsis), 20
studies involving 2384 patients;
• tuberculous pleural effusion (to evaluate the effects
of adding corticosteroids to drug regimens), 6 trials with
633 participants.
Conclusion
The systematic review and meta-analysis facilitates an
interpretation of variable results from different RCTs and
is the first step in making evidence based medicine recom-
mendations regarding corticosteroid use.
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